Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of quetiapine can be broken down into several components which progressively intensify proportional to dosage.
The general head space of quetiapine is often described as one of sleepiness, emptiness, apathy, stupor and catatonia. The specific cognitive effects can be broken down into several components which progressively intensify proportional to dosage.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Limited abuse potential exists, primarily in individuals with a history of polysubstance abuse or mental illness, and especially in incarcerated settings where access to other intoxicants is restricted. Abuse is driven by sedative and anxiolytic effects rather than antipsychotic properties. Drug-seeking behaviors have been documented, including prisoners threatening legal action or self-harm when faced with discontinuation.
Physical dependence develops with continued use, and withdrawal symptoms may occur after abrupt cessation following several weeks of steady dosing. Gradual tapering is recommended to avoid acute withdrawal syndrome. Withdrawal symptoms include nausea, vomiting, sweating, lightheadedness, insomnia, nervousness, anxiety, tachycardia, and dyskinesia.
Quetiapine has a relatively favorable overdose profile compared to other antipsychotics, with very few deaths from direct toxicity. Clinical trials demonstrated survival following overdoses of up to 30 grams, though a lethal outcome was reported after ingestion of 13.6 grams. Serum concentrations of 1-10 mg/L are typical in overdose survivors, while postmortem blood levels of 10-25 mg/L are observed in fatal cases. Most acute overdoses result only in sedation, hypotension, and tachycardia, but cardiac arrhythmia, coma, and death have occurred.
| Species | Route | Value |
|---|---|---|
| rat | oral | 2000 mg/kg |
Chronic use is associated with QT interval prolongation and an increased risk of sudden cardiac death, with risk being dose-dependent; low doses under 75 mg daily show minimal increase while higher doses approach risk levels of first-generation antipsychotics.
Long-term use is associated with weight gain averaging 1-3 kg over several months, along with hyperglycemia, elevated triglycerides, and increased diabetes risk; these metabolic effects may occur even at low doses used for insomnia.
Asymptomatic elevation of liver enzymes occurs in approximately a quarter of patients after initiating treatment; overt hepatotoxicity is rare.
Extrapyramidal symptoms and tardive dyskinesia can occur but are less common than with first-generation antipsychotics; neuroleptic malignant syndrome is a rare but potentially fatal complication.
Leukopenia and neutropenia occur in approximately 1% of patients, increasing infection risk; this typically resolves with discontinuation.
As an antipsychotic, quetiapine treats rather than induces psychosis. However, occasional reports of drug-induced mania or hypomania exist. Discontinuation may result in rebound psychosis or recurrence of the underlying condition being treated.
May lower the seizure threshold, though a clinical trial with 3,700 patients did not demonstrate an increased rate of seizures. Seizures are more commonly associated with overdose situations and may occur when combined with other drugs that lower seizure threshold.
Quetiapine was developed by the pharmaceutical company AstraZeneca during the mid-1980s through the 1990s as part of efforts to improve upon first-generation antipsychotic medications. The compound received approval from the U.S. Food and Drug Administration in September 1997 and was subsequently
Regulated as a prescription-only medicine. Not scheduled as a prohibited or controlled substance but restricted to medical dispensing.
Available by prescription only. Multiple branded and generic formulations are marketed in Canada, with the original patent having expired.
Regulated as a prescription medicine under Anlage 1 of the Arzneimittelverschreibungsverordnung (AMVV), the German regulation governing prescription requirements for medicinal products.
Available only by prescription. The substance is not scheduled under the Misuse of Drugs Act but regulated as a prescription-only medicine under pharmaceutical legislation.
Available exclusively through prescription. Not scheduled as a controlled substance under Austrian drug laws but regulated as a prescription pharmaceutical.
Unscheduled as a controlled substance but legally restricted to prescription-only status under French pharmaceutical regulations.
Classified under Abgabekategorie B in the Swiss pharmaceutical dispensing system, meaning it can only be dispensed with a valid medical prescription.
Quetiapine is not a scheduled controlled substance but requires a prescription for legal sale and distribution. FDA approved the drug in 1997. Possession without a prescription is not criminalized, though sales and distribution are restricted to licensed entities and require valid prescriptions.
19 sources cited
